Neoadjuvant chemotherapy for rectal cancer
Author Information
Author(s): Chau I, Allen M, Cunningham D, Tait D, Brown G, Hill M, Sumpter K, Rhodes A, Wotherspoon A, Norman A R, Hill A, Massey A, Prior Y
Primary Institution: Royal Marsden Hospital
Hypothesis
Can neoadjuvant systemic chemotherapy improve outcomes in patients with locally advanced rectal cancer?
Conclusion
Neoadjuvant chemotherapy prior to synchronous chemoradiation is effective in reducing tumor size and improving surgical outcomes in locally advanced rectal cancer.
Supporting Evidence
- 73.5% of patients had downstaging of their primary tumor on histological examination.
- 80.6% objective response rate after chemoradiation.
- 41% of patients had T4 tumors, and 77% underwent R0 resection.
Takeaway
This study shows that giving chemotherapy before surgery can help shrink the tumor and make it easier to remove, which is good for patients with rectal cancer.
Methodology
Patients received 12 weeks of neoadjuvant chemotherapy followed by synchronous chemoradiation and surgery.
Potential Biases
Potential selection bias due to the specific eligibility criteria for patient inclusion.
Limitations
The study had a relatively short follow-up period and included a specific patient population that may not represent all rectal cancer patients.
Participant Demographics
{"gender":{"male":26,"female":10},"median_age":63,"age_range":"40-85"}
Statistical Information
Confidence Interval
95% CI: 64–91.8%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website